Recent Press Releases

U.S. FDA Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants via Maternal Immunization

GAITHERSBURG, Md., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...

THEMIS BIOSCIENCE'S VACCINE AGAINST CHIKUNGUNYA SUCCESSFUL IN PHASE 1

Results presented at international conferences in Philadelphia and New Orleans VIENNA, Austria I November 20, 2014 I The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine...

Cipla announces a distribution agreement with Serum Institute of India for affordable paediatric vaccines in Europe

Mumbai, India (ots/PRNewswire) - Cipla Europe NV ("Cipla"), a global pharmaceutical company is delighted to announce that it has signed a distribution agreement with Serum Institute of...

TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, Nov. 18, 2014 /PRNewswire/ --TapImmune, Inc. (OTCQB: TPIV), is pleased...

Mymetics announces new collaboration to advance the development of an innovative Malaria vaccine candidate

Mymetics to apply its innovative virosome vaccine technology to develop a transmission-blocking Malaria vaccine candidate Fully funded by the PATH Malaria Vaccine Initiative (MVI), the study will...

THERAVECTYS Provides Update on Its Phase I/II Lentiviral Vector-Based Therapeutic Vaccine Trial

PARIS, France I November 18, 2014 I THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies,...

IDRI Announces $11.9M Contract To Develop Thermostable TB Vaccine

Using freeze-drying process to overcome cold-chain transportation issues SEATTLE, Nov. 19, 2014 /PRNewswire-USNewswire/ -- With the goal of developing a thermostable tuberculosis vaccine that is...

NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief Operations Officer of BioProtection Systems Corporation, Its Infectious Disease Division

AUSTIN, Texas, Nov. 14, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Thomas P. Monath, M.D. has been appointed Chief Scientific and Chief Operations...

Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma

Clearance Paves Way for First DPX-Survivac Phase II Efficacy Trial Halifax, Nova Scotia; November 19, 2014 – Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX-V: IMV), a...

TRUMENBA® (Meningococcal Group B Vaccine) is Now Available

NEW YORK--()--Pfizer Inc. (NYSE:PFE) announced today that TRUMENBA® (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent...

Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit

-Benefit observed across multiple endpoints in bevacizumab-naïve patients- -Clear signs of clinical activity in difficult to treat bevacizumab-refractory patients- HAMPTON, N.J., Nov....

ABIVAX Signs Agreement With the Finlay Institute to Commercialise Meningococcal and Typhoid Vaccines in Asia and Latin America

PARIS, November 12, 2014 /PRNewswire/ -- ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced...

VaxInnate Corporation Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints

Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering next-generation vaccine technology, announced today that enrollment has concluded in the Phase...

Large-scale study raises hopes for development of E. coli vaccine

Global comparison reveals surprisingly close relation between E. coli strains that cause traveller's diarrhoea The largest ever study of the bacterium enterotoxigenic Escherichia coli (ETEC) has...

Dendreon Reaches Agreements on Terms of Financial Restructuring

Operations to Continue Without Interruption; PROVENGE® Remains Commercially Available Commences Voluntary Chapter 11 Proceedings to Implement Restructuring Agreements SEATTLE--(BUSINESS...

Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial

- GX-188E treatment induces complete regression of precancerous cervical disease and HPV infection clearance with an unprecedented high efficacy SEONGNAM, South Korea I October 30, 2014 I Genexine,...

Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax™-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

- Funding to support GMP manufacture of VesiculoVax™-vectored vaccines for Zaire-Ebola virus, Sudan-Ebola virus, and Angola-Marburg virus that will be blended into a single formulation; rapid...

Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older

SWIFTWATER, Pa., Nov. 3, 2014 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has...

Flublok® Influenza Vaccine Now Approved for Adults Ages 18 and Older

MERIDEN, Conn., Oct. 29, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that the U.S. FDA has approved Flublok influenza vaccine for all adults aged 18 years and older, granting...

New Malaria Vaccines to Prevent Infection and Block Transmission Get a Shot in the Arm

Grant from Gates Foundation to PATH Malaria Vaccine Initiative Will Support Essential Vaccine Role in Strategy to Eradicate Malaria NEW ORLEANS, LA (2 November 2014)—In support of a bold quest...